Table 3.
Joint Effects Analysis of ALOXE3 and ALOX12 Expressions in COAD Patients OS
| Group | ALOXE3 | ALOX12 | Patients (n=438) | No. of Event | MST (days) | Crude HR (95%CI) | Crude P | Adjusted HR (95%CI) | Adjusted Pa |
|---|---|---|---|---|---|---|---|---|---|
| A | Low | Low | 120 | 17 | NA | 1 | 0.003 | 1 | 0.027 |
| B | Low | High | 99 | 21 | 1849 | 1.873 (0.987–3.552) | 0.055 | 1.263 (0.573–2.780) | 0.563 |
| C | High | Low | 99 | 18 | NA | 1.396 (0.719–2.709) | 0.325 | 1.324 (0.600–2.918) | 0.487 |
| D | High | High | 120 | 42 | 1711 | 2.710 (1.542–4.765) | 0.01 | 2.472 (1.248–4.900) | 0.009 |
Notes: aAdjusted for gender, TNM stage, CEA, KRAS and lymphatic invasion.
Abbreviations: ALOX, lipoxygenases; OS, overall survival; MST, median survival time; TCGA, The Cancer Genome Atlas; NA, not available. CEA, carcino-embryonic antigen.